This cohort study assesses incidence of primary invasive cutaneous malignant melanoma and mortality trends in Sweden, focusing on the population younger than the mean age of melanoma onset.
Risultati per: Linee guida sul melanoma cutaneo
Questo è quello che abbiamo trovato per te
Nuova linea guida sulla prevenzione dello stroke (ictus)
Alla guida dopo aver bevuto, il 5% degli italiani rischia
Dati Iss, il 66% senza cintura nei sedili posteriori, il 20% non usa il seggiolino per i bambini
Honsell (Open), melanoma, urge reparto dermatologia a Udine
Honsell (Open), melanoma, urge reparto dermatologia a Udine
Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma—What’s in a Name?—Reply
In Reply We appreciate the thoughtful response by Akama-Garren and Hartman regarding ways of reducing fear of cancer recurrence (FCR) among patients with localized melanoma. They proposed 2 potential solutions: (1) psychological support (which we also proposed) and (2) changing terminology to recategorize melanoma in situ as melanocytic lesions with low risk of progression. In this reply, we discuss both proposals.
Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma
To the Editor Mahama et al administered a qualitative survey to assess the fear of cancer recurrence for 51 survivors of localized cutaneous melanoma. The authors found that despite good prognoses, approximately 75% of survivors had fear of cancer recurrence that was negatively associated with their psychological well-being, which, as noted by the authors, aligned with prior studies among patients with melanoma. Surprisingly, Mahama et al observed similar levels of clinical fear of cancer recurrence in patients with stage 0 and stage I to IIA localized cutaneous melanoma despite the fact that patients with stage 0 have a prognosis approaching 100% 5-year melanoma-specific survival. A systematic review of 46 studies found that 82% of survivors of thyroid cancer scored 13 or higher on the Fear of Cancer Recurrence Inventory (FCRI), suggesting that patients with melanoma and thyroid cancer share high levels of cancer worry despite relatively high survival rates compared with other cancers.
Linee guida per la gestione del carcinoma epatocellulare negli adulti
Linee guida sul carcinoma ovarico, tubarico e peritoneale primario
Nuove linee guida per la gestione cardiovascolare nella chirurgia non cardiaca
Melanoma avanzato, il 43% dei pazienti è vivo a 10 anni con la doppia immunoterapia
Con nivolumab più ipilimumab. Dieci anni fa il tasso di sopravvivenza era al 25% dopo un anno
'L'Alzheimer è donna', una guida per familiari e medici
Il geriatra Fantò, ‘è un prototipo di malattia di genere’
Melanoma, immunoterapia locale uccide tumore e recluta cellule
Dal sistema immunitaria, per contrastare metastasi e recidive
NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine, Ahead of Print.
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine, Ahead of Print.
Melanoma, nuova immunoterapia funziona nei pazienti resistenti
Grazie alla combinazione con una molecola.